CNIO - Spanish National Cancer Research Centre
Susana Llanos is a staff scientist at the Centro Nacional de Investigaciones Oncológicas (CNIO) since 2004, specializing in the design and development of high-throughput screens to discover new regulators of p53 tumor suppressor activity. Key research contributions include identifying mechanisms by which newly identified repressors such as MSK2, CRPM2, and RPL37 regulate p53, as well as investigating the mTOR pathway in cellular senescence and its implications for tumor suppression. Previously, Susana served as a research associate at the Ludwig Institute for Cancer Research, focusing on the regulation of p53 by ASPP proteins, and as a post-doctoral researcher at Cancer Research UK, studying p53 activation mechanisms involving ARF protein. Susana began their research career as a Ph.D. student at the IIB Instituto de Investigaciones Biomédicas, examining the oncogenic activity of v-erbA. Susana holds a Bachelor’s degree in Biological Sciences with a focus on Molecular Biology from the Universidad Autónoma in Madrid, Spain.
This person is not in the org chart
This person is not in any teams
CNIO - Spanish National Cancer Research Centre
The Spanish National Cancer Research Centre is a public institution of excellence committed to research, diagnosis and treatment for cancer. The CNIO currently houses 22 Research Groups, organised in 7 Scientific Programmes, plus 5 Clinical Research Unit(s) that work closely with several hospitals. These scientific groups are supported by 19 Core Units that provide state-of-the-art facilities and technical expertise. The CNIO also has an Experimental Therapeutics Programme leader in academic drug discovery. Since 2011, CNIO is recognised a one of the ‘Severo Ochoa’ Centres of Excellence by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación -------------------------------- El Centro Nacional de Investigaciones Oncológicas (CNIO) es una institución pública española dedicada a la investigación, diagnóstico y tratamiento del cáncer. El CNIO cubre todo el recorrido de la I+D+i, desde la investigación básica hasta la clínica. Actualmente el CNIO tiene 22 Grupos de Investigación, organizados en 7 Programas Científicos, más 5 Unidades de Investigación Clínica que trabajan estrechamente con varios hospitales. En el CNIO hay 19 Unidades de Apoyo a la Investigación dotadas de las más modernas instalaciones y conocimientos técnicos. El CNIO también tiene un Programa de Terapias Experimentales de referencia en el descubrimiento de nuevos fármacos. Desde el 2011, el CNIO es uno de los Centros de Excelencia Severo Ochoa acreditados por la Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación.